Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma.
Mulhern RK, Palmer SL, Merchant TE, Wallace D, Kocak M, Brouwers P, Krull K, Chintagumpala M, Stargatt R, Ashley DM, Tyc VL, Kun L, Boyett J, Gajjar A.
Mulhern RK, et al.
J Clin Oncol. 2005 Aug 20;23(24):5511-9. doi: 10.1200/JCO.2005.00.703.
J Clin Oncol. 2005.
PMID: 16110011